A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations. Approximately half of the patients with EGFR-mutated NSCLC are treated with EGFR-TKIs and develop disease progression within...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chia-Feng, Liao, Chien-Yi, Chao, Heng-Sheng, Chiu, Hwa-Yen, Wang, Ting-Wei, Lee, Yen, Chen, Jyun-Ru, Shiao, Tsu-Hui, Chen, Yuh-Min, Wu, Yu-Te
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854198/
https://www.ncbi.nlm.nih.gov/pubmed/36670497
http://dx.doi.org/10.1186/s40644-023-00522-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854198/
https://www.ncbi.nlm.nih.gov/pubmed/36670497
http://dx.doi.org/10.1186/s40644-023-00522-5

Ejemplares similares